Israel Eyes Wall Street for $50B Defense IPO: Why Tel Aviv Didn't Make the Cut

Israel is moving forward with plans to take two of its most prominent state-owned defense giants public — and it's looking to the United States, not its own stock exchange, to get the deal done. The reason goes beyond access to capital: Israeli officials believe American regulators will be far more accommodating when it comes to protecting classified military secrets.

A government delegation is set to travel to the US in mid-July to explore listing options for Israel Aerospace Industries (IAI) and Rafael Advanced Defense Systems — the companies behind iconic weapons systems including the Arrow missile interceptor and the Iron Dome. Sources familiar with the mission say the core appeal of a US listing is its relative flexibility around national security disclosures, something Israeli regulators have been unwilling to offer.

The Israeli government is aiming to offload stakes of up to 30% in each company, with an ambition to close transactions before the end of the calendar year. According to Bloomberg, IAI is currently valued at approximately $33.7 billion, while Rafael's valuation stands near $20 billion — putting the combined offering in the neighborhood of $50 billion.

The disclosure challenge has long been the central obstacle. IAI's privatization was actually approved by the government six years ago but never advanced, stalled by unresolved concerns about what a publicly listed defense firm would be legally required to reveal. Both IAI and Rafael operate highly classified programs, and Israeli financial regulators have shown no willingness to carve out national security exceptions to standard disclosure rules.

By contrast, US regulators — whether at the SEC or through exchange-level negotiations with Nasdaq or the New York Stock Exchange — are seen as more open to granting exemptions for sensitive government contractors. A US listing would also activate Israel's dual-listing framework, allowing both companies to simultaneously trade on the Tel Aviv Stock Exchange under the rules of the foreign exchange, rather than local Israeli standards.

The delegation's agenda will include meetings with institutional investors, underwriters, and legal counsel to determine how US securities law applies to companies with deeply classified government contracts. Officials are also reportedly exploring whether subsidiaries of IAI and Rafael could be listed independently, a structure that might sidestep the government approval requirements that currently bind the parent entities.

Timing is adding another layer of complexity to an already intricate deal. The US regulatory environment evolved significantly earlier this year: a law enacted in March 2026 now mandates that directors and officers of foreign private issuers publicly disclose their equity holdings and transactions in real time — a sharp departure from previous norms that raises compliance costs and transparency obligations for any foreign company seeking a US listing.

Israel is wagering that customized national security exemptions can be negotiated to counterbalance these new requirements. However, no final decisions on listing venue or timeline have been officially confirmed. Rafael faces a particularly tight deadline, as the company requires government authorization before parliament dissolves ahead of national elections expected by late October.

Financially, both companies arrive at this moment from a position of strength. IAI reported record 2025 revenues of $7.4 billion alongside a net profit of $712 million, with its order backlog surpassing $30 billion for the first time in company history. Rafael's own backlog crossed the $20 billion threshold. The underlying business case for the IPO is solid — but whether Washington and Wall Street will grant the disclosure carve-outs Jerusalem is counting on remains entirely unresolved.